Drugs / IK-175
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05472506 | Mar → Apr 2023 | head and neck squamous cell carcinoma, malignant tumor of neck | Ikena Oncology | Withdrawn | No outcome recorded |
| Phase 1 | NCT04200963 | Dec 2019 → Jul 2023 | metastatic malignant neoplasm, urinary bladder cancer, urothelial carcinoma | Ikena Oncology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IK-175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04200963 ↗ |
| Action | Inhibit | “Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor” NCT04200963 ↗ |
| Route | Oral | “IK-175 PO daily” NCT04200963 ↗ |
| Target | AHR | “Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor” NCT04200963 ↗ |